Drapeau France                     Drapeau espagne                    Drapeau UK                  drapeau américain              drapeau émirats 
Obesity  Diabetes  Erection Ejaculation Prostate Prostate adenoma Prostate atrophy Prostate cancer Immunity Hair loss
Arteriosclerosis Hypertension Coronary disease Anemia Heart infarct Muscular weakness Osteoporosis Arthrosis Depression Parkinson Alzheimer
 
Home white on blue 32x32 SITE MAP GEORGES DEBLED MD. TV - VIDEO BOOKS
ANTI AGING SOLUTIONS FOR MAN









AGELESS MAN   AMAZON 2017-2022































































































































































































































































 

History of andropause disease

AGELESS MAN   AMAZON 2017-2022

 

Andropause disease did not exist before 1952 for simple reason that the word "andropause" did not exist . This word was introduced in  French dictionary in 1952.

Specific treatment of andropause disease did not exist before 1967 when mesterolone was put on the market for first time.

There was no specific treatment for andropause disease before 1968 when Bruchovsky and Wilson  (pdf) from Texas University, Dallas, discovered the conversion of testosterone to dihydrotestosterone in the sexual organs. The same year, Anderson and Liao (pdf) from the University of Chicago,have discovered specific receptors for dihydrotestosterone in the nuclei of prostate cells

Andropause disease diagnosis did not exist before 1974 year when radioimmulological studies (RIA) where available in daily medical practice.

Radiommunological analyses proportioning dihydrotestosterone, testosterone and their metabolites were consequently realizable.

Androgenic disease of andropause was described for the first time in 1987 and published on January 4th 1988 by Georges Debled after 14 years' clinical and radio-immunological studies.

 Clinical and radioimmunological studies of Georges DEBLED MD. demonstrated since 40 years that a decrease of production in male hormones produces and worsens the sexual involution in man; cardiovascular diseases, arteriosclerosis, angina pectoris, coronary thrombosis, high sugar, high cholesterol and lipids in the blood; arthrosis, stiffness and rheumatism of joins ; nervous breakdown and brain involution.

 

Those phenomenon were described in two pioneer-books  by Dr Georges DEBLED: L'Andropause, cause, conséquences et remèdes", Maloine, Paris 1988 and "Au-delà de cette limite votre ticket est toujours valable", Albin Michel, Paris 1992 et 1994.

    In 1992, at an international congress on ageing in Dallas, Dr Georges DEBLED presented his theory, according to which the fall in testosterone secretion is responsible for male climacteric and ageing illnesses:

    DEBLED G. The male climacteric, prime cause of sex involution. The tenth annual international symposium on man and his environment in health and disease. February 27 - March 1, 1992, Dallas. Texas. U.S.A.

    DEBLED G. The male climacteric, prime cause of aging. The tenth annual international symposium on man and his environment in health and disease. February 27 - March 1, 1992, Dallas. Texas. U.S.A.

    Conference of  Dr Georges Debled on andropause disease at the Barnes Foundation USA February 25th 1992  (Video) You Tube  (56 minutes)

Since this time of many scientific papers  have confirmed this work:

In 1997,  21 INSERM Unit in  France confirmed the increase of cardiovascular risk when testosterone secretion is low in "healthy" adult man  : "Association between plasma total testosterone and cardiovascular risk factors in healthy adult men"  in the Journal of Clinical Endocrinology and Metabolism (Vol 82, N° 2, p. : 682- 685). This study known as the  Telecom study investigated two groups of men during 8 years comparing their blood testosterone levels.  Download pdf.

               First group with normal testosterone during 8 years did not show any increase of vascular risk during this period. 

               Second group with a decrease of  blood testosterone along the 8 years demonstrated a significant increase of cardiovascular risk.

Recent Publications confirming  hypogonadism of the final phase of  andropause disease

In 2006 a study has demonstrated an increased mortality in men with low testosterone  Download pdf.

Andropause disease in short  (powerpoint) logo powerpoint

 

The expressiom "andropause disease" corresponds to a terminological

use of collocations
The main symptom is the progressive decrease of sexual activity in the elderly man (andropause)
This symptom may be accompanied by general disorders corresponding to  diseases of aging (andropause disease). It is indeed a disease that has a definition of its own.
As this disease is unknown, its definition is absent from all dictionaries.
The expression "androgenic disease of andropause" is also suitable for this concept published in January 1988

 

Bibliography

1. DEBLED G.- L'Andropause, cause, conséquences et remèdes. Maloine, Paris, 1988.

2. DEBLED G. Andropause. 1: Le castrat: un modèle "expérimental". N° 4308 - 24 mai 1989. Le Quotidien du Médecin. Paris.

3. DEBLED G. Andropause 2: Dépister pour reculer le vieillissement prématuré.  N° 43 l 3 - 3 l mai 1989. Le Quotidien du Médecin. Paris.

4. DEBLED G. Andropause 3: Sclérose des corps caverneux: le fatalisme n'est plus de mise. N° 4318 - 7 juin 1989. Le Quotidien du Médecin. Paris.

5. DEBLED G. Andropause 4: Les troubles "émotionnels" ne doivent pas cacher l'impuissance organique.  N° 4323 - 14 juin 1989. Le Quotidien du Médecin. Paris.

6. DEBLED G. Andropause 5: Les troubles de l'éjaculation. N° 4328 - 21 juin 1989. Le Quotidien du Médecin. Paris.

7. DEBLED G. Andropause 6: Les perturbations de la miction. N° 4334 - 29 juin 1989. Le Quotidien du Médecin. Paris.

8. DEBLED G. Andropause 7: L'atrophie de la prostate. N° 4372 - 26 septembre 1989. Le Quotidien du Médecin. Paris. Le Quotidien du Médecin. Paris.

9. DEBLED G. Andropause 8: Des difficultés mictionnelles à l'insuffisance rénale. N° 4377 - 3 octobre 1989. Le Quotidien du Médecin. Paris.

10. DEBLED G. Andropause 9: Un âge où "tout se dégrade".N° 4382 - 10 octobre 1989. Le Quotidien du Médecin. Paris

11. DEBLED G. Andropause 10: Les hormones sexuelles de l'homme. N4337 - 17 octobre l 989. Le Quotidien du Médecin. Paris.

12. DEBLED G. Andropause 11: Le généraliste et l'exploration du vieillissement sexuel. N° 4397 - 31 octobre 1989. Le Quotidien du Médecin. Paris.

13. DEBLED G. Andropause 12: Les androgènes favorisent-ils l'apparition d'un cancer  de la prostate? N° 4401 - 7 novembre 1989. Le Quotidien du Médecin. Paris.

14. DEBLED G. Andropause 13: Le traitement hormonal. N° 4422 - 6 décembre 1989. Le Quotidien du Médecin. Paris.

15. DEBLED G. Au-delà de celle limite votre ticket est toujours valables. Albin Michel.1992.Paris.

16. DEBLED G. The male climacteric, prime cause of sex involution. The Tenth annual international symposium on man and his environment in health and disease. February 27-March 1, 1992. Dallas. Texas. U.S.A.

17. DEBLED G. The male climacteric, prime cause of aging. The Tenth annual international symposium on man and his environment in health and disease. February 27-March 1, 1992. Dallas. Texas. U.S.A.

18. DEBLED G. Le traitement hormonal du vieillissement  sexuel de l'homme. Journal de médecine esthétique et de chirurgie dermatologique. Vol XXII- N° 85: 7 - 16, 1995

Course

 AMERICAN MEDICAL ASSOCIATION  (AMA) 1993 -Teaching Seminar

American Academy of family physicians

DEBLED G: MD. The " andropause : The Male climacteric and its consequences" teaching seminar-- Acceptable for 15 hours of prescribed credits by the American Academy of family physicians, and for 15 hours of category I AMA credits. Broda O. Barnes M.D. Research Foundation Inc.25-28 March 1993

Scientific Communications

1994

DEBLED G. L'homme après 50 ans : l'andropause. Le traitement médical du vieillissement sexuel chez l'homme après 50 ans. Congrès National de Médecine esthétique et de chirurgie dermatologique. Paris. 23-25 septembre 1994.

1995

DEBLED G. L'andropause, mythe ou réalité ? Journées Millavoises de gynécologie obstétrique et de pédiatrie. Millau, les 9 et 10 juin 1995

1996

DEBLED G. Les principes de l'andropause. Congrès de gynécologie. 29 mars 1996. Paris.

1997

DEBLED G. Prévention des sénescences. La base du maintien du système de vie. Société Belge de Médecine Esthétique. Premier congrès européen de médecine esthétique et de chirurgie dermatologique et esthétique. Bruxelles 7-8-9 novembre 1997

1998

DEBLED G.Treatment of testosterone deficiency in aging male patients.The European International Conference on Quality of Life and Longevity Medecine.  Brussels 24-26 September 1998.

1999

DEBLED G. Maladies cardio-vasculaires et longévité. First congress of the EAAA (European Anti-Aging Association). Brussels 25th September 1999.

DEBLED G. Incidences hormonales dans les alopécies. Second European congress of aesthetic Medicine and dermatological and plastic surgery. Brussels, 24-26 September 1999. 

DEBLED G. Les nouveaux traitements hormonaux et leur importance en Médecine Esthétique. Second European congress of aesthetic Medicine and dermatological and plastic surgery. Brussels, 24-26 September 1999.-

DEBLED G. L'importance des traitements hormonaux dans le maintien de l'apparence physique. Second European congress of aesthetic Medicine and dermatological and plastic surgery. Brussels, 24-26 September 1999.

 2000

DEBLED G. Comment faire le diagnostic et le traitement de l’andropause ? Premier congrès Ibérique de médecine esthétique. Lisbonne, 28-30 avril 2000.

DEBLED G. Anti-Ageing for Men 13ème congrès International de Médecine Esthétique. Monaco, 4 Novembre 2000

 2001

 DEBLED G. Androgénothérapie chez l’homme. Second congress of the EAAA (European Anti-Aging Association) Knokke le Zoute  21th September 2001

DEBLED G: L'andropause, cause, conséquences et remèdes. Société Tunisienne des Biothérapies. Congrès du XXe Anniversaire. Tunis, 25-28 Octobre 2001

2002

DEBLED G.Testosterona y derivados Primero congreso de la SEMAL (Sociedad española de Medicina Envejecimiento) Sevilla 29 noviembre 2002

2003

DEBLED G. Androgènes, clefs du traitement anti-âge ? Congress of the EAAA (European Anti-Aging Association) dans le cadre de l’IMCAS Paris 11th January 2003.

2004

DEBLED G. Androgénothérapie anti-âge chez l’homme. Third congress of the EAAA (European Anti-Aging Association) Brussels 5th November 2004.

2005

Testosterona. Congreso de la SEMAL (Sociedad española de Medicina Envejecimiento). Sevilla 29 noviembre 2002.

2006

DEBLED G. La enfermedad “andropausia”. Congreso internacional de medicina anti envejecimiento. Septiembre 21-22 y 23 de 2006 Club Militar de Bogotá. Bogotá D.C.

DEBLED G. Atrofia de la próstata y envejecimiento. Congreso internacional de medicina anti envejecimiento. Septiembre 21-22 y 23 de 2006 Club Militar de Bogotá. Bogotá D.C.

DEBLED G. La enfermedad “andropausia”. Mi experiencia hace 32 años. International congress of anti-aging Medicine Vº congreso de la sociedad española de medicina anti envejecimiento y longevidad. Madrid 3,4 y 5 de Noviembre 2006. Hotel Melia Castilla. Madrid.